1. The Nevro acquisition is subject to shareholder and regulatory approval, but Globus Medical expects the deal to close in the second quarter, CEO Dan Scavilla said as transcribed by Motley Fool.
2. Mr. Scavilla said the company expects Nevro to be accretive to earnings in the second year of operations.
3. The Nevro acquisition will allow Globus Medical to touch a $2 billion market space, Mr. Scavilla said. Nevro is known for its spine products and spinal cord stimulator technologies.
“We believe our high-frequency technology offers clinically superior solutions that can alter the standard of care for patients,” Mr. Scavilla said. “Nevro technology has potential beyond its current application to benefit our cranial enabling technology, next-generation spinal implants, data mining, and other areas of our business.”
